BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Blend Therapeutics Lands $16 Million, Names a CEO


12/18/2012 6:48:53 AM

Blend Therapeutics, one-year-old pre-clinical biotech focused on oncology drugs, has raised $16 million in Series B financing and named the former head of Sunovion Pharmaceuticals as its new CEO.

Mark Iwicki was named president and CEO, and has been named to the board of directors of the Watertown company, which emerged from stealth in January. The company is based on nanoparticle technology developed by Omid Farokhzad of Brigham and Women’s Hospital (BWH) and Harvard Medical School (HMS), and Robert Langer and Dr. Stephen J. Lippard of MIT. Iwicki has more than 23 years of experience in the pharmaceutical industry, including most recently as CEO of Sunovion and CCO of Sepracor.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->